Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2344-2351
doi: 10.1161/CIRCULATIONAHA.106.685313
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cutlip, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cutlip, D. E.
Related Collections
Right arrow Catheter-based coronary interventions: stents

(Circulation. 2007;115:2344-2351.)
© 2007 American Heart Association, Inc.


Special Reports

Clinical End Points in Coronary Stent Trials

A Case for Standardized Definitions

Donald E. Cutlip, MD; Stephan Windecker, MD; Roxana Mehran, MD; Ashley Boam, MSBE; David J. Cohen, MD; Gerrit-Anne van Es, PhD, MSc; P. Gabriel Steg, MD; Marie-angèle Morel, BSc; Laura Mauri, MD, MSc; Pascal Vranckx, MD; Eugene McFadden, MD; Alexandra Lansky, MD; Martial Hamon, MD; Mitchell W. Krucoff, MD; Patrick W. Serruys, MD, on behalf of the Academic Research Consortium

From Harvard Clinical Research Institute (D.E.C., D.J.C., L.M.), Harvard Medical School, Boston, Mass; University Hospital (S.W.), Bern, Switzerland; Cardiovascular Research Foundation (R.M., A.L.), Columbia University, New York, NY; The US Food and Drug Administration (A.B.), Rockville, Md; Cardialysis (G.v.-E., M.M.), Rotterdam, the Netherlands; CHU Bichat (P.G.S.), Paris, France; Hospital Virga Jesse (P.V.), Hasselt, Belgium; University Hospital (E.M.), Cork, Ireland; CHU Caen (M.H.), Normandy, France; Duke Clinical Research Institute (M.W.K.), Duke University, Durham, NC; Erasmus Medical Center (P.W.S.), Thoraxcenter, Rotterdam, the Netherlands.

Correspondence to Donald E. Cutlip, MD, Harvard Clinical Research Institute, 930 Commonwealth Avenue, Boston, MA 02215. E-mail dcutlip{at}bidmc.harvard.edu

Background— Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation.

Methods and Results— The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in Washington, DC, in January 2006 and in Dublin, Ireland, in June 2006, sponsored by the Academic Research Consortium and including representatives of the US Food and Drug Administration and all device manufacturers who were working with the Food and Drug Administration on drug-eluting stent clinical trial programs, were focused on consensus end point definitions for drug-eluting stent evaluations. The effort was pursued with the objective to establish consistency among end point definitions and provide consensus recommendations. On the basis of considerations from historical legacy to key pathophysiological mechanisms and relevance to clinical interpretability, criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed. The broadly based consensus end point definitions in this document may be usefully applied or recognized for regulatory and clinical trial purposes.

Conclusion— Although consensus criteria will inevitably include certain arbitrary features, consensus criteria for clinical end points provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.


Key Words: restenosis • stents • thrombosis • clinical trials




This article has been cited by other articles:


Home page
CirculationHome page
M. E. Pfisterer
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised
Circulation, September 9, 2008; 118(11): 1117 - 1119.
[Full Text] [PDF]


Home page
CirculationHome page
H. Kelbaek, L. Thuesen, S. Helqvist, P. Clemmensen, L. Klovgaard, A. Kaltoft, B. Andersen, H. Thuesen, T. Engstrom, H. E. Botker, et al.
Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial
Circulation, September 9, 2008; 118(11): 1155 - 1162.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. G. Ellis, C. D. O'Shaughnessy, S. L. Martin, K. Kent, T. McGarry, M. A. Turco, D. J. Kereiakes, J. J. Popma, M. Friedman, J. Koglin, et al.
Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
Eur. Heart J., July 1, 2008; 29(13): 1625 - 1634.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
JAMA, June 25, 2008; 299(24): 2868 - 2876.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Chechi, S. Vecchio, G. Vittori, G. Giuliani, A. Lilli, G. Spaziani, L. Consoli, G. Baldereschi, G. G.L. Biondi-Zoccai, I. Sheiban, et al.
ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2396 - 2402.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J., June 11, 2008; (2008) ehn253v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Meliga, H. M. Garcia-Garcia, M. Valgimigli, A. Chieffo, G. Biondi-Zoccai, A. O. Maree, S. Cook, L. Reardon, C. Moretti, S. De Servi, et al.
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2212 - 2219.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. Austin, J. P. Pell, K. G. Oldroyd, P. Agostoni, P. Vermeersch, O. C. Marroquin, S. R. Mulukutla, and K. E. Kip
Bare-Metal versus Drug-Eluting Coronary Stents
N. Engl. J. Med., June 5, 2008; 358(23): 2516 - 2518.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al.
Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2011 - 2016.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, et al.
Bivalirudin during Primary PCI in Acute Myocardial Infarction
N. Engl. J. Med., May 22, 2008; 358(21): 2218 - 2230.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri
Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1844 - 1853.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. W. Stone, M. Midei, W. Newman, M. Sanz, J. B. Hermiller, J. Williams, N. Farhat, K. W. Mahaffey, D. E. Cutlip, P. J. Fitzgerald, et al.
Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
JAMA, April 23, 2008; 299(16): 1903 - 1913.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. R. Patel and D. R. Holmes Jr
Next-Generation Drug-Eluting Stents: A Spirited Step Forward or More of the Same
JAMA, April 23, 2008; 299(16): 1952 - 1953.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1543 - 1552.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al.
Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
JAMA, April 16, 2008; 299(15): 1788 - 1799.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. J. Zellweger, C. Kaiser, H. P. Brunner-La Rocca, P. T. Buser, S. Osswald, P. Weiss, J. Mueller-Brand, M. E. Pfisterer, and for the BASKET Investigators
Value and Limitations of Target-Vessel Ischemia in Predicting Late Clinical Events After Drug-Eluting Stent Implantation
J. Nucl. Med., April 1, 2008; 49(4): 550 - 556.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Pfisterer, H. P. Brunner-La Rocca, and C. Kaiser
The balance of risks and benefits of drug-eluting versus bare-metal stents.
J. Am. Coll. Cardiol., March 4, 2008; 51(9): 972 - 972.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. L. Dauerman
Percutaneous Coronary Intervention Pharmacology From a Triangle to a Square.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 698 - 700.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 701 - 707.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Kirtane, S. G. Ellis, K. D. Dawkins, A. Colombo, E. Grube, J. J. Popma, M. Fahy, M. B. Leon, J. W. Moses, R. Mehran, et al.
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 708 - 715.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52.
[Abstract] [PDF]


Home page
J Am Coll Cardiol IntvHome page
R. Rogacka, A. Chieffo, I. Michev, F. Airoldi, A. Latib, J. Cosgrave, M. Montorfano, M. Carlino, G. M. Sangiorgi, A. Castelli, et al.
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation
J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 56 - 61.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X. Pan
Concerns in the SESAMI Trial
J. Am. Coll. Cardiol., January 22, 2008; 51(3): 329 - 330.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Menichelli
Reply
J. Am. Coll. Cardiol., January 22, 2008; 51(3): 330 - 330.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. A. Harrington, V. Hasselblad, and R. M. Califf
Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?
J. Am. Coll. Cardiol., January 1, 2008; 51(1): 33 - 36.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. Wijns and E. Braunwald
Advancing the Knowledge Base on the Efficacy Safety Ratio With Drug-Eluting Stents: Contributions From the European Society of Cardiology Congress, Vienna, Austria, September 1 5, 2007
J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2431 - 2433.
[Full Text] [PDF]


Home page
CirculationHome page
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation, October 23, 2007; 116(17): 1952 - 1965.
[Full Text] [PDF]


Home page
CirculationHome page
J. W. Riddell, L. Chiche, B. Plaud, and M. Hamon
Coronary Stents and Noncardiac Surgery
Circulation, October 16, 2007; 116(16): e378 - e382.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M.-K. Hong, G. S. Mintz, C. W. Lee, D.-W. Park, S.-W. Lee, Y.-H. Kim, D.-H. Kang, S.-S. Cheong, J.-K. Song, J.-J. Kim, et al.
Impact of Late Drug-Eluting Stent Malapposition on 3-Year Clinical Events
J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1515 - 1516.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Kereiakes
The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1381 - 1385.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M.-C. Morice, P. W. Serruys, P. Barragan, C. Bode, G.-A. Van Es, H.-P. Stoll, D. Snead, L. Mauri, D. E. Cutlip, and E. Sousa
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents: Five-Year Results of the RAVEL Trial
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1299 - 1304.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. G. Steg
Revascularization Before Noncardiac Surgery: Is There an Impact of Drug-Eluting Stent Thrombosis?
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1398 - 1398.
[Full Text] [PDF]


Home page
CirculationHome page
F. Airoldi, A. Colombo, N. Morici, A. Latib, J. Cosgrave, L. Buellesfeld, E. Bonizzoni, M. Carlino, U. Gerckens, C. Godino, et al.
Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment
Circulation, August 14, 2007; 116(7): 745 - 754.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari, D. Barbieri, G. Parrinello, G. Percoco, and R. Ferrari
Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction: Results From the STRATEGY Study
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 138 - 145.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 119 - 127.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. W. Krucoff, A. Boam, and D. G. Schultz
Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward?
Circulation, June 12, 2007; 115(23): 2990 - 2994.
[Full Text] [PDF]